P0825: Combination of advanced therapies in anal fistulas of Crohn's disease: efficacy, tolerance and predictive factorsECCO'25Year: 2025
Authors: Fathallah, N.(1)*;Pagano, M.(1);Skoufou, M.(1);Lazareth, M.(1);Alam, A.A.(1);Barré, A.(1);Roland, D.(1);Safa Far, E.(1);Rentien, A.L.(1);Chambenois, E.(2);Haouari, M.A.(3);de Parades, V.(1);
(1)GH Paris Saint-Joseph, Proctology, Paris, France;(2)Hôpital Saint-Antoine, Radiology, Paris, France;(3)GH Paris Saint-Joseph, Radiology, Paris, France;
P0826: Switching to standard-dose subcutaneous vedolizumab increases the percentage of patients in biochemical remission even in those intensified with intravenous vedolizumab: one year results of a Spanish multicentre observational study.ECCO'25Year: 2025
Authors: Andres Pascual, L.(1)*;Iborra, M.(2);Vicente, R.(3);Arias , L.(4);Nos, P.(2);Royo-Esteban, A.(5);Sicilia , B.(4);
(1)Complejo Asistencial Universitario de León, Gastroenterology., León, Spain;(2)Hospital Universitario y Politécnico La Fe. Valencia- España., Gastroenterology. IBD Unit, Valencia, Spain;(3)Hospital Universitario MIguel Servet. Zaragoza. España, Gastroenterology. IBD Unit, Zaragoza, Spain;(4)Hospital Universitario de Burgos, Gastroenterology. IBD Unit, Burgos, Spain;(5)Hospital Universitario Miguel Servet- Zaragoza- España, Gastroenterology. IBD Unit, Zaragoza, Spain;
1. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colomben JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22;369(8):711-21.
2. Vermiere S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's Disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27-38.
3. Buisson A, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R et al. Comparative Acceptability of Therapeutic Maintenance Regimens in Patients with Inflammatory Bowel Disease: Results from the Nationwide ACCEPT2 Study. Inflamm. Bowel Dis. 2023, 29, 579–588.
4. Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022 Jun;55(11):1389-1401.
5. Oršić Frič V, Borzan V, Šahinović I, Borzan A, Kurbel S. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory. Bowel Disease Patients: Single-Center Experience. Pharmaceuticals (Basel). 2023 Feb 5;16(2):239.
P0827: Single cell RNA sequencing analysis of specific cell subsets for predicting anti-TNF treatment response in Korean patients with ulcerative colitisECCO'25Year: 2025
Authors: Kim, H.G.(1)*;Jeon, S.R.(1);Jung, Y.H.(2);Kim, J.O.(1);Choi, S.(2);Ko, B.M.(3);Hwang, W.C.(4);
(1)Soonchunhyang University Seoul Hospital, Digestive Disease Center- Institute for Digestive Research, Seoul, Korea- Republic Of;(2)Soonchunhyang University Cheonan Hospital, Division of Gastroenterology, Cheonan, Korea- Republic Of;(3)Soonchunhyang University Bucheon Hospital, Division of Gastroenterology and Hepatology, Bucheon, Korea- Republic Of;(4)College of Medicine- College of Medicine Hanyang Institute of Bioscience and Biotechnology- Hanyang University, Department of Pre‑Medicine, Seoul, Korea- Republic Of;
P0828: The impact of etrasimod on neutrophils in the ELEVATE UC clinical programmeECCO'25Year: 2025
Authors: Allez, M.(1)*;Verstockt, B.(2,3);Crosby, C.M.(4);Ryan, R.D.(5);Fellmann, M.(6);Kunina, E.(6);Lazin, K.(6);Dalam, A.B.(7);Wu, J.(8);Karolina, W.(9);Siegmund, B.(10,11);
(1)Hôpital Saint Louis- APHP- Université Paris Cité, Department of Gastroenterology, Paris, France;(2)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism- Translational Research in GI Disorders, Leuven, Belgium;(4)., Pfizer Inc, La Jolla- CA, United States;(5)., Pfizer Inc, San Francisco- CA, United States;(6)., Pfizer AG, Zürich, Switzerland;(7)., Pfizer Inc, Manila, Philippines;(8)., Pfizer Inc, Cambridge- MA, United States;(9)., Pfizer Canada, Kirkland- QC, Canada;(10)Charité – Universitätsmedizin Berlin, Med. Klinik für Gastroenterologie- Infektiologie- Rheumatologie, Berlin, Germany;(11)Freie Universität Berlin- Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany;
1. Sandborn WJ et al. Lancet 2023; 401: 1159–1171.
Pfizer’s generative artificial intelligence tool MAIA was used to assist production of the abstract first draft. Authors reviewed/edited and take responsibility for the content.
P0829: ‘Temporary’ faecal diversion in refractory Crohn’s Disease: too good to be true? A retrospective, single centre analysis.ECCO'25Year: 2025
Authors: Alliet, B.(1)*;Bislenghi, G.(2);Vermeire, S.(1);Guedelha Sabino, J.P.(1);Ferrante, M.(1);D'Hoore, A.(2);Verstockt, B.(1);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;
P0830: Use of FK-adalimumab biosimilar (MSB 11022) in context of biologic switch in Inflammatory Bowel Diseases : 6 months data of the real-world IDEA studyECCO'25Year: 2025
Authors: Peyrin-Biroulet, L.(1)*;Bouhnik, Y.(1);Hebuterne, X.(2);Fumery, M.(3);Taxonera, C.(4);Gutierrez-Casbas, A.(5);Howaldt, S.(6);Stein, J.(7);Lindsay, J.(8);Monnet, J.(9);Simoes, E.(9);Dolfi, F.(10);
(1)Groupe Hopspitalier Ambroise Paré, Institut des MICI, Neuilly-sur-Seine, France;(2)CHU de NIce and University Cote d'Azur, Service de gastro-entérologie et nutrition clinique, Nice, France;(3)CHU d'Amiens, Service d'Hépatogastroenterologie, Amiens, France;(4)Hospital Universitario Clinico San Carlos, IBD unit, Madrid, Spain;(5)Hospital General Universitario de Alicante, Service of gastro-enterology, Alicante, Spain;(6)Hamburgisches Forschungsinstitut fure Chronische Darmerkrankungen-, Gastroenterology service, Hamburg, Germany;(7)FEBG- AGAF DGD Kliniken Frankfurt Sachsenhausen Leiter der Abteilung Gastroenterologie, Gastroenterology, Frankfurt am Main, Germany;(8)The Royal London Hospital, Barts Health NHS Trust-, London, United Kingdom;(9)Fresenius kabi Biopharma, Biostatistics, Eysins, Switzerland;(10)Fresenius Kabi Biopharma, Global Medical Affairs, Eysins, Switzerland;
P0831: Improving efficiency in early phase clinical trials for inflammatory bowel disease through use of external control armsECCO'25Year: 2025
Authors: Neustifter, B.(1)*;Galluzzi, A.(1);Ma, C.(2,3,4);Jairath, V.(2,5,6);
(1)Alimentiv Inc., Statistical Center of Excellence, London, Canada;(2)Alimentiv Inc., Medical Research & Development, London, Canada;(3)University of Calgary, Division of Gastroenterology and Hepatology- Cumming School of Medicine, Calgary, Canada;(4)University of Calgary, Department of Community Health Sciences, Calgary, Canada;(5)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(6)Western University, Department of Epidemiology and Biostatistics, London, Canada;
1 Harris MF, Wichary J, Zadnik M, Reinisch W. Competition for clinical trials in inflammatory bowel diseases. Gastroenterology. 2019;157(6):1457-1461. doi:10.1053/j.gastro.2019.08.020
2 Ma C, Solitano V, Danese S, Jairath V. The future of clinical trials in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2024;Jul 16:S1542-3565(24)00635-9. doi:10.1016/j.cgh.2024.06.036
3 Zayadi A, Edge R, Parker CE, Macdonald JK, Neustifter B, Chang J, et al. Use of external control arms in immune-mediated inflammatory diseases: a systematic review. BMJ Open. 2023;13(12):e076677. doi:10.1136/bmjopen-2023-076677
4 Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, et al. Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn's disease (EXPLORER). Clin Gastroenterol Hepatol. 2024;22(7):1487-1496. doi:10.1016/j.cgh.2023.09.010
P0832: Real-world effectiveness of risankizumab in Crohn's Disease: The UK ExperienceECCO'25Year: 2025
Authors: Elford, A.(1)*;Plevris, N.(1);Constantine-Cooke, N.(2);Shah, K.(3);Faloon, S.(3);Colwill, M.(4);Akbani, U.(5);Morgan, H.(6);Ghoda, A.(7);Radia, C.(8);Young , D.(9);Morris, S.(10);Anwar-Hashim, Z.(11);Hassall , J.(12);Thomas, M.(13);Dyall , L.(14);Clough, J.(15);Mahmood , T.(16);Mohammed, A.(17);Rudling, R.(18);Dhar, A.(19);Gaya, D.(20);Verma, A.(21);Seenan, J.(17);Johnston , E.(16);Goel, R.(15);Hicks , L.(14);Sebastian, S.(13);Hale, M.(12);Harvey, P.(11);Cooney, R.(10);Cummings , F.(22);Kent, A.(8);King, A.(7);Limdi, J.(6);Sellinger, C.(5);Pollok, R.(4);Parkes, G.(3);Lees, C.(1);
(1)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Institute of Genetics and Cancer- University of Edinburgh- Western General Hospital, MRC Human Genetics Unit, Edinburgh, United Kingdom;(3)The Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(4)St George’s University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(5)Leeds Teaching Hospitals NHS Trust, Leeds Gastroenterology Institute, Leeds, United Kingdom;(6)Northern Care Alliance NHS Foundation Trust, Department of Gastroenterology, Manchester, United Kingdom;(7)Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology, Newcastle Upon Tyne, United Kingdom;(8)King's College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(9)University Hospital Southampton NHS Foundation Trust, Pharmacy department, Southampton, United Kingdom;(10)University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology- Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom;(11)Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(12)Sheffield Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology, Sheffield, United Kingdom;(13)Hull University Teaching Hospitals NHS Trust, Department of Gastroenterology, Hull, United Kingdom;(14)Imperial College Healthcare NHS Trust, Department of Gastroenterology, London, United Kingdom;(15)Kingston Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(16)Chelsea and Westminster Hospitals NHS Foundation Trust, Department of Gastroenterology, Middlesex, United Kingdom;(17)NHS Greater Glasgow & Clyde, Department of Gastroenterology, Glascow, United Kingdom;(18)The Mid Yorkshire Teaching NHS Trust, Pharmacy Department, York, United Kingdom;(19)County Durham and Darlington NHS Foundation Trust, Department of Gastroenterology, Durham, United Kingdom;(20)Glascow Royal Infirmary- NHS Greater Glasgow and Clyde, Department of Gastroenterology, Glascow, United Kingdom;(21)Kettering General Hospital, Department of Gastroenterology, Kettering, United Kingdom;(22)University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom; The PAN UK risankizumab CD study group
P0833: Trajectories of response in patients with moderately-to-severely active Crohn’s disease treated with mirikizumab or ustekinumab: Post hoc results from the VIVID-1 studyECCO'25Year: 2025
Authors: Schreiber , S.W.(1)*;Clemow , D.B.(2);Yu , G.(2);Keefer , L.A.(3);Ananthakrishnan , A.N.(4);D'Haens , G.(5);Deepak , P.(6);Kocchar , G.S.(7);Melmed , G.Y.(8);Chen , Y.F.(2);Moses , R.E.(2);
(1)University Hospital Schleswig-Holstein- Christian-Albrecht University of Kiel, Department of Internal Medicine, Kiel, Germany;(2)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(4)Massachusetts General Hospital and Harvard Medical School, Division of Gastroenterology, Boston, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Washington University in St. Louis School of Medicine, Division of Gastroenterology, St. Louis, United States;(7)Allegheny Health Network, Division of Gastroenterology- Hepatology- and Nutrition, Pittsburgh, United States;(8)Cedars Sinai Medical Center, Karsh Division of Gastroenterology and Hepatology, Los Angeles, United States;
1. M Ferrante, S Danese, M Chen, et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study, Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i7–i9, https://doi.org/10.1093/ecco-jcc/jjad212.0005.
P0834: Mucosal improvement and histologic healing with amiselimod for active Ulcerative Colitis: a phase 2, randomised, placebo-controlled trialECCO'25Year: 2025
Authors: Schreiber, S.W.(1)*;Laitman, A.P.(2);Heimanson, Z.(2);Israel, R.J.(3);Lee, J.(4);Hanauer, S.B.(5);
(1)University Hospital Schleswig-Holstein, Department of Internal Medicine I - Gastroenterology- Hepatology- Nutrition and Geriatrics, Kiel, Germany;(2)Salix Pharmaceuticals, Medical Affairs, Bridgewater, United States;(3)Bausch Health US- LLC, Clinical and Medical Affairs, Bridgewater, United States;(4)Bausch Health US- LLC, Clinical Affairs, Bridgewater, United States;(5)Northwestern University, Medicine, Chicago, United States;
P0835: AI-guided generation and development of HXN-1001, a highly potent and half-life extended anti-TL1A antibodyECCO'25Year: 2025
Authors: Huang, J.(1);Ran, H.(1);Li, S.(1);Su, C.(1);Chen, C.(1);Liu, D.(1);Pan, Y.(1);Xu, X.(1);Chen, X.(1);Fei, K.(1);Tian, J.(1);Wang, M.(1);Tian, L.(1);Peng, J.(1);Zhu, Z.(1)*;
(1)Helixon Therapeutics, Drug discovery, New York, United States;
P0836: Real-world application of the Crohn’s disease clinical decision support tool (CDST) in both intravenous and subcutaneous vedolizumabECCO'25Year: 2025
Authors: Choon, X.Y.(1)*;Yeo, J.H.(2);White, C.(1);Thorpe, S.(3);Bapt, S.(3);Gecse, K.(1);Dart, R.(1);Anderson, S.(1);Mawdsley, J.(1);Harrow, P.(2);Ray, S.(1);Irving, P.(1);Samaan, M.(1);
(1)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)University College London Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(3)King's College London, Medical School, London, United Kingdom;
1. Dulai PS et al. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 Sep;155(3):687-695.e10. doi: 10.1053/j.gastro.2018.05.039. Epub 2018 May 30. PMID: 29857091; PMCID: PMC6419724.
2. P Dulai, D Lindner, C Agboton, H Alric, G Bamias, L Peyrin-Biroulet. P354 Application of the clinical decision support tool to predict treatment outcomes in Crohn’s Disease patients treated with vedolizumab subcutaneous formulation, Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i490–i491, https://doi.org/10.1093/ecco-jcc/jjac190.0484
P0837: Prevalence of the HLA-DQA1*05 phenotype in a cohort of Spanish patients with Inflammatory Bowel Disease, and its association with the response to first anti-TNF therapy in real-world settings.ECCO'25Year: 2025
Authors: De Castro Parga, M.L.(1)*;Ucha, P.(1);Sanroman, L.(1);Santamaría , A.(1);Hernández, V.(1);Martínez-Cadilla, J.(1);García-Morales, N.(1);Rodríguez-Prada, I.(1);
(1)Hospital Alvaro Cunqueiro CHUVI Universitary Hospital Complex of Vigo, Gastroenterology, Vigo, Spain; GUT Diseases Galicia Sur Research Institute (IIS Galicia Sur) SERGAS.UVIGO
Spencer EA, Stachelski J, Dervieux T et al. Failure to achieve target drug concentrations during induction and not HLA-DQA1∗05 carriage is associated with antidrug antibody formation in patients with Inflammatory Bowel Disease. Gastroenterology. 2022;162(6):1746-48.
Pascual-Oliver A, Casas-Deza D, Cuarán C et al. HLA-DQA1*05 was not associated with primary nonresponse or loss of response to first anti-TNF in real-world Inflammatory Bowel Disease patients. Inflamm Bowel Dis.2024; 3:30 (6):922-929.
P0838: The clinical outcomes of Inflammatory Bowel Disease after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysisECCO'25Year: 2025
Authors: Zhou, J.(1)*;Sneek, D.(1);Hansen , B.(2);den Hoed, C.(1,3);de Jong, M.(1);Pan , Q.(1);van der Meer, A.J.(1,3);Li , P.(1);de Vries , A.C.(1);
(1)Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)Erasmus Medical Center, Department of Epidemiology and Biostatistics, Rotterdam, The Netherlands;(3)Erasmus Medical Center, Erasmus MC Transplant Institute, Rotterdam, The Netherlands;
P0839: Monitoring disease activity using intestinal ultrasonography in patients with Crohn’s disease treated with risankizumabECCO'25Year: 2025
Authors: Miyakawa, M.(1)*;Shimoyama, K.(1);Hamada, T.(1);Shimazaki, H.(1);Sugiyama, K.(1,2);Nasuno, M.(1);Tanaka, H.(1);
(1)Sapporo IBD Clinic, Department of Inflammatory Bowel Disease, Sapporo, Japan;(2)Sapporo Central Hospital, Department of Gastroenterology, Sapporo, Japan;
1) Nasuno M, Shimazaki H, Nojima M, Hamada T, Sugiyama K, Miyakawa M, Tanaka H. Serum leucine-rich alpha-2 glycoprotein levels for predicting active ultrasonographic findings in intestinal lesions of patients with Crohn’s disease in clinical remission. Medicine (Baltimore). 2023;102(32):e34628. doi: 10.1097/MD.0000000000034628.
P0840: Health related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open label maintenance studyECCO'25Year: 2025
Authors: Vermeire, S.(1);Sands, B.E.(2);Rabbat, C.(3);Shan, K.(4);Dolan, C.M.(5);Cataldi, F.(3);Jacobstein, D.(6);Fine, J.T.(7)*;
(1)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Abivax, Medical Affairs, Paris, France;(4)Abivax, Biometrics, Paris, France;(5)CMD Consulting Inc, Health Economics and Outcomes Research, Sandy, United States;(6)Abivax, Clinical Development, Paris, France;(7)Abivax, Health Economics and Outcomes Research, Paris, France;
P0841: Hospitalisation and surgery rates in patients with Ulcerative Colitis and Crohn’s disease treated with subcutaneous vedolizumab: Long-term findings from the VISIBLE OLE studyECCO'25Year: 2025
Authors: Vermeire, S.(1)*;Jones, S.(2);Velazco, N.(2);Agboton, C.(2);Wojtowicz, A.M.(2);Young, L.(2);Phillips, R.(3);Loftus- Jr., E.V.(4);Danese, S.(5);D’Haens, G.(6);
(1)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(2)Takeda Pharmaceuticals, Takeda Development Center Americas- Inc., Cambridge, United States;(3)GI PROS Inc., GI PROS Inc., Naples, United States;(4)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(5)IRCCS Ospedale San Raffaele- Università Vita-Salute San Raffaele, Division of Gastroenterology and Gastrointestinal Endoscopy, Milan, Italy;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;
P0842: Paediatric Inflammatory Bowel Diseases: novel agents on the therapeutic horizonECCO'25Year: 2025
Authors: Gupte, D.(1);Suthar, N.R.(2);MacDonald, J.K.(3);Colman, R.J.(4);Feagan, B.(3,5,6);Hanzel, J.(3,7);Ma, C.(3,8,9);Jairath, V.(3,5,6);Crowley, E.(3,10)*;
(1)McMaster University, Department of Pediatrics, Hamilton, Canada;(2)Western University- London Health Sciences Centre- Children's Hospital Western Ontario, Department of Paediatrics- Division of Paediatric Gastroenterology, London, Canada;(3)Alimentiv Inc., Medical R&D, London, Canada;(4)Stanford University School of Medicine, Department of Pediatrics- Division of Pediatric Gastroenterology- Hepatology and Nutrition, Stanford, United States;(5)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(6)Western University, Department of Epidemiology and Biostatistics, London, Canada;(7)University Medical Center Ljubljana- University of Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia;(8)University of Calgary, Department of Medicine- Division of Gastroenterology & Hepatology, Calgary, Canada;(9)University of Calgary, Department of Community Health Sciences, Calgary, Canada;(10)Western University, Department of Paediatrics- Division of Paediatric Gastroenterology- Hepatology and Nutrition, London, Canada;
1. Crowley E, Ma C, Andic M, Feagan BG, Griffiths AM, Jairath V. Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2022;16(2):331-5
2. U.S Food and Drug Administration. Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-inflammatory-bowel-disease-developing-drugs-treatment
3. Created in BioRender. Suthar, N. (2024) BioRender.com/l43j981
P0843: Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results at Week 12 from the phase 3 GRAVITI studyECCO'25Year: 2025
Authors: D'Haens, G.(1)*;Hisamatsu, T.(2);Steinwurz, F.(3);Hart, A.(4);Liu, W.(5);Olurinde, M.(6);Ngqawa, P.(6);Yang, Z.(6);Merrall, E.(7);Terry, N.A.(6);Sands, B.E.(8);Panaccione, R.(9);
(1)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(2)Kyorin University, Gastroenterology, Tokyo, Japan;(3)Hospital Israelita Albert Einstein, Gastroenterology, São Paulo, Brazil;(4)London North-West University Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(5)The Second People's Hospital of Changzhou- The Third Affiliated Hospital of Nanjing Medical University, Gastroenterology, Changzhou, China;(6)Janssen Research & Development- LLC, Immunology, Spring House, United States;(7)Janssen Vaccines and Prevention BV, Immunology, Leiden, The Netherlands;(8)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(9)University of Calgary, Gastroenterology, Calgary, Canada;
1) Panaccione R, Hart A, Steinwurz F, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through week 48 from the phase 3 GRAVITI study. Presented at American College of Gastroenterology 2024.
P0844: Real-world effectiveness of vedolizumab in managing refractory pouchitis: a multicenter study on intravenous to subcutaneous transition.ECCO'25Year: 2025
Authors: Gimeno-Pitarch, L.(1);Minguez, A.(2);Cespedes, E.(3);Ferreiro, R.(4);Martín-Arranz , M.D.(5);Sicilia , B.(6);Lorca , I.(7);Huguet, J.M.(8);Mesonero, F.(9);Vicente, R.(10);Nos, P.(2);Iborra, M.(2)*;
(1)Hospital General Universitario de Castellón, Gastroenterology, Castellon, Spain;(2)Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain;(3)Hospital Universitario Vall d` Hebron, Gastroenterology, Barcelona, Spain;(4)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(5)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(6)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(7)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(8)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(9)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(10)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;
